Skip to content
naulon

Not checkedNot checked for notices yet.

Efficacy and prognostic predictors of first-generation EGFR TKI-targeted therapy in patients with EGFR-mutated advanced non-small cell lung cancer

HONG Yaping, HUANG Yunjian, HUANG Zhangzhou, CHEN Shengjia, ZHONG Qiaofeng, ZENG Hongfu, ZHUANG Wu

Zhongguo aizheng zazhi · 2022

doi:10.19401/j.cnki.1007-3639.2022.07.006 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Background and purpose: Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment has become the first-line standard treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutation. However, 10%-30% of NSCLC patients with EGFR sensitive mutation still have primary drug resistance when receiving TKI targeted therapy. Therefore, to study the clinical efficacy of EGFR-TKI and find out its prognostic predictors has important significance for the treatment of advanced NSCLC patients with EGFR sensitive mutation. The purpose of this research was to evaluate the efficacy of icotinib as first-line treatment in patients with EGFR-mutant advanced NSCLC and investigate the prognostic predictors. Methods: A total of 258 stage ⅢB-Ⅳ NSCLC patients with EGFR mutation who were admitted to Fujian Cancer Hospital from January 2016 to November 2017 were selected. One hundred and eighteen advanced NSCLC patients with EGFR mutation were enrolled, and baseline circulating tumor DNA (ctDNA) EGFR-mutant status was determined using the plasma test. All these patients received icotinib 125mg three times a day. The χ2 test was used to compare the differences in clinicopathological characteristics between different EGFR mutation groups. Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan-Meier survival curve. The log-rank test was used for univariate analysis, and the COX regression model was used for multivariate analysis. Results: The objective response rate (ORR) of 118 patients was 62.7% (95% CI: 53.9%-71.6%), the disease control rate (DCR) was 92.4% (95% CI: 87.5%-97.2%), and the median PFS was 11.3months (95% CI: 9.1-13.5 months), and the median OS was 32.0 months (95% CI: 26.9-37.1 months). No statistically significant difference was found in the clinicopathological characteristics between different EGFR expression types (P>0.05), while the best efficacy between different EGFR mutation groups was significantly different (P=0.040). Univariate analysis showed that EGFR mutation status in plasma ctDNA test was not correlated with PFS and OS of patients (P>0.05). Multivariate analysis showed that baseline lactate dehydrogenase (LDH) expression level, EGFR types, pleural effusion and the best curative effect might be independent factors of PFS. The patient’s N stage, bone metastasis, time to PFS and presence of EGFR T790M mutation might be independent predictors of OS. Conclusion: Icotinib as first-line treatment was effective in EGFR-mutant advanced NSCLC patients. The EGFR mutation status in plasma ctDNA test was not correlated with the clinical efficacy of patients. Bone metastasis was found to be an independent factor of worse prognosis.

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.